Welcome, please login

INVestIgation of rheumatiC AF Treatment Using vitamin K antagonists, rivaroxaban or aspirin Studies

© 2024 Population Health Research Institute
Unauthorized use of this system is strictly prohibited. Your IP 192.168.175.44

This program is a comprehensive evaluation of RVHD, AF/flutter and stroke. It includes three major components:

1. A multi-centre registry of RVHD

2. A prospective, randomized, parallel group, open-label clinical trial of rivaroxaban versus standard VKA therapy to evaluate non-inferiority of rivaroxaban to VKA, with testing for superiority if non-inferiority is satisfied.

3. A prospective, randomized, open-label superiority trial comparing rivaroxaban to aspirin in high risk patients either with AF and unsuitable for VKA or without AF and with high risk factors.